https://www.aigom.it/wp-content/uploads/2022/12/logo-sito.png00Alessia Losihttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngAlessia Losi2023-05-29 07:19:012023-10-25 13:39:36Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial
https://www.aigom.it/wp-content/uploads/2022/12/logo-sito.png00Alessia Losihttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngAlessia Losi2023-04-17 10:13:542023-04-17 10:20:09US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer
https://www.aigom.it/wp-content/uploads/2022/12/logo-sito.png00Alessia Losihttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngAlessia Losi2023-04-07 12:57:032023-04-07 12:59:21Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.
https://www.aigom.it/wp-content/uploads/2022/12/logo-sito.png00Alessia Losihttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngAlessia Losi2023-02-28 13:26:482023-02-28 13:26:48Intra-individual comparison of ¹⁸F-sodium fluoride PET–CT and ⁹⁹mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial
https://www.aigom.it/wp-content/uploads/2023/02/BLOOD-PRESSURE.jpg821581Alessia Losihttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngAlessia Losi2023-02-21 13:20:222023-02-21 13:20:22Blood Pressure Classification Using the 2017 ACC/AHA Guideline and Heart Failure in Patients with Cancer
https://www.aigom.it/wp-content/uploads/2022/12/logo-sito.png00Alessia Losihttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngAlessia Losi2023-02-16 14:07:402023-02-21 13:17:19Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
https://www.aigom.it/wp-content/uploads/2022/12/logo-sito.png00Alessia Losihttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngAlessia Losi2023-02-16 14:01:132023-02-16 14:03:10Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
https://www.aigom.it/wp-content/uploads/2023/02/MARTUGIXAB.jpg821581Alessia Losihttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngAlessia Losi2023-02-16 13:50:322023-02-16 13:56:40MARGITUXIMAB vs TRASTUZUMAB in pazienti con carcinoma mammario HER2-positivo avanzato pretrattato: risultati dello studio randomizzato di fase III SOPHIA.
